Navigation Links
The MDS foundation supports vidaza's recommendation for European approval

The Myelodysplastic Syndromes (MDS) Foundation supports the positive opinion from the European Union's Committee for Medicinal Products for Human Use (CHMP) recommending approval of VIDAZA (azacitidine) for specific types of MDS patients, including those with high-risk MDS, chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML).

The CHMP positive opinion was based upon data from the AZA-001 trial, which found that VIDAZA nearly doubled the two-year survival rate for higher-risk MDS patients compared to conventional care regimens (CCR) with a mean survival of 24.5 months compared to 15 months for patients who received CCR.

"We are very encouraged by the CHMP's recommendation for marketing approval for VIDAZA," said Kathy Heptinstall, Operating Director of the Myelodysplastic Syndromes Foundation, "The MDS Foundation is committed to making sure that patients in need are aware of and have access to new treatments, like VIDAZA, that can help patients to live longer and allow them to have a better quality of life."

The AZA-001 trial also showed that, VIDAZA delays the progression of MDS to acute myeloid leukemia (AML). Roughly 30 percent of patient diagnosed with MDS will progress to AML. The delay in progression is especially significant because patients with MDS are typically over the age of 65. According to the National Institute of Health, in this patient group, the average 5-year survival rate after diagnosis with AML is only approximately four percent.

MDS is a primary neoplasm of the bone marrow that is more prevalent than any of the leukemias. MDS affects the function of blood cells; red blood cells, white blood cells or platelets. The incidence of MDS is underestimated.


Contact: Kathy Heptinstall
The Myelodysplastic Syndromes Foundation

Page: 1

Related biology news :

1. Meyskens honored with AACR-Prevent Cancer Foundation award
2. Parkinsons Disease Foundation announces award of $150,000
3. The Camille & Henry Dreyfus Foundation to host important symposium on chemistry and the environment
4. UT Southwestern researcher awarded Gates Foundation grant for novel vaccine development
5. National Science Foundation grant expands UMCES oyster research
6. Dunn Foundation gives Rice $3M for collaborative research grants
7. National Science Foundation grants Clemson professors award to develop nanoprobes
8. Entertainment Software Association Foundation awards grant to FAS for immune attack
9. A major prize in the chemical sciences announced by the Camille and Henry Dreyfus Foundation
10. UT Knoxville wins 2 $3M National Science Foundation research and education grants
11. The MDS Foundation supports the FDAs decision to expand vidaza label to include survival data
Post Your Comments:
(Date:5/9/2016)... May 9, 2016 Elevay is ... to expanding freedom for high net worth professionals seeking ... today,s globally connected world, there is still no substitute ... ever duplicate sealing your deal with a firm handshake. ... by taking advantage of citizenship via investment programs like ...
(Date:4/26/2016)... DUBLIN , April 27, 2016 ... of the  "Global Multi-modal Biometrics Market 2016-2020"  report ... ) , The analysts forecast ... a CAGR of 15.49% during the period 2016-2020.  ... a number of sectors such as the healthcare, ...
(Date:4/13/2016)... 13, 2016  IMPOWER physicians supporting Medicaid patients in ... new clinical standard in telehealth thanks to a new ... higi platform, IMPOWER patients can routinely track key health ... mass index, and, when they opt in, share them ... to a local retail location at no cost. By ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. ... the faculty of the University of North Carolina Kenan-Flagler Business School ... entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international efforts, leading ...
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, one of ... their brand, UP4™ Probiotics, into Target stores nationwide. The company, which has been ... Target to its list of well-respected retailers. This list includes such fine stores ...
(Date:6/23/2016)... , June 23, 2016 Houston Methodist ... the Cy-Fair Sports Association to serve as their ... agreement, Houston Methodist Willowbrook will provide sponsorship support, ... connectivity with association coaches, volunteers, athletes and families. ... the Cy-Fair Sports Association and to bring Houston ...
Breaking Biology Technology: